| Item Type | Name |
|
Concept
|
Adenine
|
|
Concept
|
Academic Medical Centers
|
|
Concept
|
Acetylation
|
|
Concept
|
Acid Phosphatase
|
|
Concept
|
Acquired Immunodeficiency Syndrome
|
|
Concept
|
Aged, 80 and over
|
|
Concept
|
Aldosterone
|
|
Concept
|
Alkaline Phosphatase
|
|
Concept
|
Absorption
|
|
Concept
|
Acrylamides
|
|
Concept
|
Acetaminophen
|
|
Concept
|
Adolescent
|
|
Concept
|
Aged
|
|
Concept
|
Complementary Therapies
|
|
Concept
|
Analgesics, Opioid
|
|
Concept
|
Biotransformation
|
|
Concept
|
Blood Pressure
|
|
Concept
|
Administration, Oral
|
|
Concept
|
Adrenocorticotropic Hormone
|
|
Concept
|
Alcohol Dehydrogenase
|
|
Concept
|
Adult
|
|
Concept
|
Busulfan
|
|
Concept
|
Carbazoles
|
|
Concept
|
Cardiac Output
|
|
Concept
|
Analgesics
|
|
Concept
|
Anesthesiology
|
|
Concept
|
Anthraquinones
|
|
Concept
|
Aminoquinolines
|
|
Concept
|
Anesthetics
|
|
Concept
|
Anthropometry
|
|
Concept
|
Antibodies, Monoclonal
|
|
Concept
|
Codeine
|
|
Concept
|
Asthma
|
|
Concept
|
Cyclosporins
|
|
Concept
|
Antidotes
|
|
Concept
|
Aryl Hydrocarbon Hydroxylases
|
|
Concept
|
B-Lymphocytes
|
|
Concept
|
Base Sequence
|
|
Concept
|
Benzamides
|
|
Concept
|
Biological Availability
|
|
Concept
|
Carmustine
|
|
Concept
|
Bayes Theorem
|
|
Concept
|
Dipeptides
|
|
Concept
|
DNA Damage
|
|
Concept
|
Body Height
|
|
Concept
|
Azacitidine
|
|
Concept
|
Benzofurans
|
|
Concept
|
Pan troglodytes
|
|
Concept
|
Astrocytoma
|
|
Concept
|
Drug Packaging
|
|
Concept
|
Bilirubin
|
|
Concept
|
Blast Crisis
|
|
Concept
|
Bleomycin
|
|
Concept
|
Body Weight
|
|
Concept
|
Cancer Care Facilities
|
|
Concept
|
Bone Marrow Examination
|
|
Concept
|
Cattle
|
|
Concept
|
Child
|
|
Concept
|
Flavonoids
|
|
Concept
|
Floxuridine
|
|
Concept
|
Coma
|
|
Concept
|
Chemistry, Pharmaceutical
|
|
Concept
|
Burkitt Lymphoma
|
|
Concept
|
Cisplatin
|
|
Concept
|
Leucovorin
|
|
Concept
|
Caffeine
|
|
Concept
|
Crigler-Najjar Syndrome
|
|
Concept
|
Demography
|
|
Concept
|
Hockey
|
|
Concept
|
Cosyntropin
|
|
Concept
|
Hydroxylation
|
|
Concept
|
Hymecromone
|
|
Concept
|
DNA-Binding Proteins
|
|
Concept
|
Drug Industry
|
|
Concept
|
Drug Synergism
|
|
Concept
|
Immunosuppressive Agents
|
|
Concept
|
Interleukin-2
|
|
Concept
|
Cytochrome P-450 Enzyme System
|
|
Concept
|
Decision Support Techniques
|
|
Concept
|
DNA Repair
|
|
Concept
|
Child, Preschool
|
|
Concept
|
DNA Mutational Analysis
|
|
Concept
|
DNA, Neoplasm
|
|
Concept
|
Dogs
|
|
Concept
|
Cyclophosphamide
|
|
Concept
|
Daunorubicin
|
|
Concept
|
Dehydroepiandrosterone
|
|
Concept
|
Ferredoxin-NADP Reductase
|
|
Concept
|
Tegafur
|
|
Concept
|
Glucocorticoids
|
|
Concept
|
Erythrocyte Count
|
|
Concept
|
Erythropoietin
|
|
Concept
|
Etoposide
|
|
Concept
|
Coformycin
|
|
Concept
|
Cytarabine
|
|
Concept
|
DNA Topoisomerases, Type II
|
|
Concept
|
Drug Interactions
|
|
Concept
|
Drug Resistance
|
|
Concept
|
Eating
|
|
Concept
|
Food
|
|
Concept
|
Inactivation, Metabolic
|
|
Concept
|
Indoles
|
|
Concept
|
Interferons
|
|
Concept
|
Methyltransferases
|
|
Concept
|
Microtubule-Associated Proteins
|
|
Concept
|
Fluorouracil
|
|
Concept
|
Food Labeling
|
|
Concept
|
Deoxyadenosines
|
|
Concept
|
Glioma
|
|
Concept
|
Glycosylation
|
|
Concept
|
Glioblastoma
|
|
Concept
|
Fasting
|
|
Concept
|
Neoplasms, Hormone-Dependent
|
|
Concept
|
Killer Cells, Natural
|
|
Concept
|
Forced Expiratory Volume
|
|
Concept
|
Government Agencies
|
|
Concept
|
DNA Topoisomerases, Type I
|
|
Concept
|
Dose-Response Relationship, Drug
|
|
Concept
|
Drug Labeling
|
|
Concept
|
Economics, Medical
|
|
Concept
|
Hydralazine
|
|
Concept
|
Liposomes
|
|
Concept
|
Liver Neoplasms
|
|
Concept
|
Efficiency
|
|
Concept
|
Hydrocortisone
|
|
Concept
|
Hypnotics and Sedatives
|
|
Concept
|
Flow Cytometry
|
|
Concept
|
Infant
|
|
Concept
|
Investments
|
|
Concept
|
Genetics, Population
|
|
Concept
|
Glutathione
|
|
Concept
|
Leukocytes, Mononuclear
|
|
Concept
|
Medicare
|
|
Concept
|
Lymphoproliferative Disorders
|
|
Concept
|
Carcinoma, Hepatocellular
|
|
Concept
|
Heterocyclic Compounds, 4 or More Rings
|
|
Concept
|
Medical Records
|
|
Concept
|
Pharmacogenetics
|
|
Concept
|
Pilot Projects
|
|
Concept
|
Lymphopenia
|
|
Concept
|
Macaca mulatta
|
|
Concept
|
Midazolam
|
|
Concept
|
Neoplasm Transplantation
|
|
Concept
|
Nogalamycin
|
|
Concept
|
Pneumonia, Viral
|
|
Concept
|
Mass Media
|
|
Concept
|
Estrogen Antagonists
|
|
Concept
|
Immunohistochemistry
|
|
Concept
|
Indazoles
|
|
Concept
|
Orchiectomy
|
|
Concept
|
Organoplatinum Compounds
|
|
Concept
|
Molecular Sequence Data
|
|
Concept
|
Oxidoreductases, N-Demethylating
|
|
Concept
|
Pain
|
|
Concept
|
Pancreatic Neoplasms
|
|
Concept
|
Meperidine
|
|
Concept
|
Methotrexate
|
|
Concept
|
Mice, Inbred C57BL
|
|
Concept
|
Middle Aged
|
|
Concept
|
Random Allocation
|
|
Concept
|
Mitoxantrone
|
|
Concept
|
Mycosis Fungoides
|
|
Concept
|
Myelodysplastic Syndromes
|
|
Concept
|
Cricetinae
|
|
Concept
|
Health Policy
|
|
Concept
|
Hot Temperature
|
|
Concept
|
Patents as Topic
|
|
Concept
|
Patient Education as Topic
|
|
Concept
|
Peptide Fragments
|
|
Concept
|
Rheumatology
|
|
Concept
|
Neutrophils
|
|
Concept
|
Nitriles
|
|
Concept
|
Leukemia L1210
|
|
Concept
|
Phosphorylcholine
|
|
Concept
|
Ovarian Neoplasms
|
|
Concept
|
Oxidation-Reduction
|
|
Concept
|
Oxidoreductases
|
|
Concept
|
Pain, Postoperative
|
|
Concept
|
Liver
|
|
Concept
|
Safety
|
|
Concept
|
Oxycodone
|
|
Concept
|
Patient Advocacy
|
|
Concept
|
Pentoxifylline
|
|
Concept
|
Peripheral Nervous System Diseases
|
|
Concept
|
Melphalan
|
|
Concept
|
Patients
|
|
Concept
|
Sex Characteristics
|
|
Concept
|
Pharmacology, Clinical
|
|
Concept
|
Phosphorylation
|
|
Concept
|
Physician's Role
|
|
Concept
|
Morpholines
|
|
Concept
|
Motivation
|
|
Concept
|
Mouth Mucosa
|
|
Concept
|
Nitrosamines
|
|
Concept
|
Pharmacy and Therapeutics Committee
|
|
Concept
|
Phenobarbital
|
|
Concept
|
Drug Prescriptions
|
|
Concept
|
Probability
|
|
Concept
|
Prostatic Neoplasms
|
|
Concept
|
Protein-Tyrosine Kinases
|
|
Concept
|
Forecasting
|
|
Concept
|
Frozen Sections
|
|
Concept
|
Genetic Markers
|
|
Concept
|
Hodgkin Disease
|
|
Concept
|
Mixed Function Oxygenases
|
|
Concept
|
Troleandomycin
|
|
Concept
|
Hyponatremia
|
|
Concept
|
Idoxuridine
|
|
Concept
|
Imipramine
|
|
Concept
|
Immunoenzyme Techniques
|
|
Concept
|
Regression Analysis
|
|
Concept
|
Guanine
|
|
Concept
|
Research Support as Topic
|
|
Concept
|
Risk Factors
|
|
Concept
|
Verapamil
|
|
Concept
|
Protein Kinases
|
|
Concept
|
Quinoxalines
|
|
Concept
|
Inpatients
|
|
Concept
|
Interferon-gamma
|
|
Concept
|
Intestinal Absorption
|
|
Concept
|
Intestinal Mucosa
|
|
Concept
|
Carcinoma, Merkel Cell
|
|
Concept
|
Sensory Receptor Cells
|
|
Concept
|
Leukemia, B-Cell
|
|
Concept
|
Interleukin-6
|
|
Concept
|
Specialization
|
|
Concept
|
Lactams
|
|
Concept
|
Respiratory Insufficiency
|
|
Concept
|
Risk
|
|
Concept
|
Thiotepa
|
|
Concept
|
Thymidine
|
|
Concept
|
Societies, Medical
|
|
Concept
|
Sulfonic Acids
|
|
Concept
|
Humans
|
|
Concept
|
Leukocyte Count
|
|
Concept
|
Body Mass Index
|
|
Concept
|
Linear Models
|
|
Concept
|
Organizational Policy
|
|
Concept
|
Tomography, X-Ray Computed
|
|
Concept
|
Technology, Pharmaceutical
|
|
Concept
|
Thalidomide
|
|
Concept
|
Software
|
|
Concept
|
Statistics as Topic
|
|
Concept
|
Informed Consent
|
|
Concept
|
Interferon Type I
|
|
Concept
|
Tetrahydrofolates
|
|
Concept
|
Thionucleotides
|
|
Concept
|
Lymphoma, T-Cell, Cutaneous
|
|
Concept
|
Motor Neuron Disease
|
|
Concept
|
Truth Disclosure
|
|
Concept
|
United States Food and Drug Administration
|
|
Concept
|
Succinylcholine
|
|
Concept
|
Uridine Diphosphate
|
|
Concept
|
Practice Guidelines as Topic
|
|
Concept
|
Warfarin
|
|
Concept
|
Drug Design
|
|
Concept
|
Isoquinolines
|
|
Concept
|
Ketoconazole
|
|
Concept
|
Universities
|
|
Concept
|
Multicenter Studies as Topic
|
|
Concept
|
Leukemia, Lymphocytic, Chronic, B-Cell
|
|
Concept
|
Isotretinoin
|
|
Concept
|
Mercaptopurine
|
|
Concept
|
Lymphoma, Follicular
|
|
Concept
|
Carcinoma, Neuroendocrine
|
|
Concept
|
Hematopoietic Stem Cell Transplantation
|
|
Concept
|
Oncogene Proteins, Fusion
|
|
Concept
|
Proportional Hazards Models
|
|
Concept
|
Risk Assessment
|
|
Concept
|
Drug Resistance, Neoplasm
|
|
Concept
|
Developed Countries
|
|
Concept
|
Myeloablative Agonists
|
|
Concept
|
Reverse Transcriptase Polymerase Chain Reaction
|
|
Concept
|
Oligodeoxyribonucleotides, Antisense
|
|
Concept
|
Mitogen-Activated Protein Kinases
|
|
Concept
|
Vinca Alkaloids
|
|
Concept
|
Vitamins
|
|
Concept
|
Carboplatin
|
|
Concept
|
Treatment Refusal
|
|
Concept
|
Myosin Type II
|
|
Concept
|
Propofol
|
|
Concept
|
Up-Regulation
|
|
Concept
|
Quinolones
|
|
Concept
|
DNA, Antisense
|
|
Concept
|
Medicine
|
|
Concept
|
Mephenytoin
|
|
Concept
|
Metabolic Clearance Rate
|
|
Concept
|
Neoplasms, Second Primary
|
|
Concept
|
Leukemia, Prolymphocytic
|
|
Concept
|
Observer Variation
|
|
Concept
|
Pentostatin
|
|
Concept
|
2-Chloroadenosine
|
|
Concept
|
Radiosurgery
|
|
Concept
|
Fluvoxamine
|
|
Concept
|
Lymphatic Metastasis
|
|
Concept
|
Lymphoma
|
|
Concept
|
Morphine
|
|
Concept
|
Program Evaluation
|
|
Concept
|
Causality
|
|
Concept
|
Least-Squares Analysis
|
|
Concept
|
Lymphocytes, Tumor-Infiltrating
|
|
Concept
|
Comorbidity
|
|
Concept
|
Private Sector
|
|
Concept
|
Rats, Sprague-Dawley
|
|
Concept
|
Rats, Wistar
|
|
Concept
|
Drug Approval
|
|
Concept
|
Human Genome Project
|
|
Concept
|
Sequence Analysis, DNA
|
|
Concept
|
Prostate-Specific Antigen
|
|
Concept
|
Protein Structure, Tertiary
|
|
Concept
|
Receptors, Endothelin
|
|
Concept
|
Postmenopause
|
|
Concept
|
Medical Oncology
|
|
Concept
|
Melanoma
|
|
Concept
|
Menopause
|
|
Concept
|
Microtubules
|
|
Concept
|
Paraffin Embedding
|
|
Concept
|
Treatment Outcome
|
|
Concept
|
Mycophenolic Acid
|
|
Concept
|
National Institutes of Health (U.S.)
|
|
Concept
|
Neoplasm Metastasis
|
|
Concept
|
Neoplasm Recurrence, Local
|
|
Concept
|
Neoplasms, Experimental
|
|
Concept
|
Dihydrouracil Dehydrogenase (NADP)
|
|
Concept
|
Oligodeoxyribonucleotides
|
|
Concept
|
Neurites
|
|
Concept
|
Tissue Fixation
|
|
Concept
|
Point Mutation
|
|
Concept
|
Interferon-alpha
|
|
Concept
|
Nedocromil
|
|
Concept
|
Mice, Knockout
|
|
Concept
|
DNA, Complementary
|
|
Concept
|
Sample Size
|
|
Concept
|
Disease Progression
|
|
Concept
|
ras Proteins
|
|
Concept
|
Hepatocyte Nuclear Factor 1-alpha
|
|
Concept
|
International Normalized Ratio
|
|
Concept
|
Rats, Inbred Dahl
|
|
Concept
|
Angiogenesis Inhibitors
|
|
Concept
|
Cytochrome P-450 CYP2D6
|
|
Concept
|
Kv1.3 Potassium Channel
|
|
Concept
|
Receptor Protein-Tyrosine Kinases
|
|
Concept
|
Analgesics, Non-Narcotic
|
|
Concept
|
Osteolysis
|
|
Concept
|
Disclosure
|
|
Concept
|
Myosin Heavy Chains
|
|
Concept
|
Public Sector
|
|
Concept
|
Parkinson Disease
|
|
Concept
|
Cladribine
|
|
Concept
|
In Situ Hybridization, Fluorescence
|
|
Concept
|
Government Regulation
|
|
Concept
|
Federal Government
|
|
Concept
|
Organizations, Nonprofit
|
|
Concept
|
Patient Protection and Affordable Care Act
|
|
Concept
|
Gene-Environment Interaction
|
|
Concept
|
Empirical Research
|
|
Concept
|
Therapeutic Human Experimentation
|
|
Concept
|
Vascular Endothelial Growth Factor Receptor-2
|
|
Concept
|
Endostatins
|
|
Concept
|
Receptors, G-Protein-Coupled
|
|
Concept
|
Population Groups
|
|
Concept
|
Nontherapeutic Human Experimentation
|
|
Concept
|
Equilibrative Nucleoside Transporter 1
|
|
Concept
|
Herb-Drug Interactions
|
|
Concept
|
Methylenetetrahydrofolate Reductase (NADPH2)
|
|
Concept
|
Hepatocyte Nuclear Factor 1
|
|
Concept
|
Lactams, Macrocyclic
|
|
Concept
|
Area Under Curve
|
|
Concept
|
Budesonide
|
|
Concept
|
Proto-Oncogene Proteins c-raf
|
|
Concept
|
Amino Acid Substitution
|
|
Concept
|
Proto-Oncogene Proteins B-raf
|
|
Concept
|
Patient Participation
|
|
Concept
|
Oligonucleotide Array Sequence Analysis
|
|
Concept
|
Evidence-Based Medicine
|
|
Concept
|
Personal Autonomy
|
|
Concept
|
Health Care Sector
|
|
Concept
|
Perioperative Care
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p21
|
|
Concept
|
Proto-Oncogene Proteins c-ret
|
|
Concept
|
Periodicals as Topic
|
|
Concept
|
Pharmacokinetics
|
|
Concept
|
Phosphotransferases
|
|
Concept
|
Phthalazines
|
|
Concept
|
Phenylenediamines
|
|
Concept
|
Platelet Count
|
|
Concept
|
Platinum
|
|
Concept
|
Podophyllotoxin
|
|
Concept
|
Polyethylene Glycols
|
|
Concept
|
Placebos
|
|
Concept
|
Organic Anion Transporters, Sodium-Independent
|
|
Concept
|
Prodrugs
|
|
Concept
|
Promoter Regions, Genetic
|
|
Concept
|
Prostatectomy
|
|
Concept
|
Mice
|
|
Concept
|
Protein Kinase C
|
|
Concept
|
Quinazolines
|
|
Concept
|
National Cancer Institute (U.S.)
|
|
Concept
|
DNA Breaks, Double-Stranded
|
|
Concept
|
Research Design
|
|
Concept
|
Schools, Medical
|
|
Concept
|
Structure-Activity Relationship
|
|
Concept
|
Sulfonamides
|
|
Concept
|
Taiwan
|
|
Concept
|
Tea
|
|
Concept
|
Biomedical Research
|
|
Concept
|
Therapeutic Equivalency
|
|
Concept
|
Tissue Distribution
|
|
Concept
|
Receptors, Vascular Endothelial Growth Factor
|
|
Concept
|
Luciferases, Firefly
|
|
Concept
|
Rats
|
|
Concept
|
Prescription Drugs
|
|
Concept
|
Class I Phosphatidylinositol 3-Kinases
|
|
Concept
|
TOR Serine-Threonine Kinases
|
|
Concept
|
Adenosine A2 Receptor Antagonists
|
|
Concept
|
Antibodies, Monoclonal, Humanized
|
|
Concept
|
Human Umbilical Vein Endothelial Cells
|
|
Concept
|
Uracil
|
|
Concept
|
Sex Factors
|
|
Concept
|
Stereoisomerism
|
|
Concept
|
Vincristine
|
|
Concept
|
Adaptor Proteins, Signal Transducing
|
|
Concept
|
Suramin
|
|
Concept
|
Blotting, Western
|
|
Concept
|
Epirubicin
|
|
Concept
|
Cyclin-Dependent Kinase Inhibitor p15
|
|
Concept
|
NFATC Transcription Factors
|
|
Concept
|
Logistic Models
|
|
Concept
|
DNA Copy Number Variations
|
|
Concept
|
Lymphoma, B-Cell
|
|
Concept
|
CD4-CD8 Ratio
|
|
Concept
|
Cyclosporine
|
|
Concept
|
Electronic Health Records
|
|
Concept
|
Vinblastine
|
|
Concept
|
Reproducibility of Results
|
|
Concept
|
Zidovudine
|
|
Concept
|
Patient Satisfaction
|
|
Concept
|
Clinical Medicine
|
|
Concept
|
Platelet Transfusion
|
|
Concept
|
Survival Rate
|
|
Concept
|
Odds Ratio
|
|
Concept
|
Lymphocyte Subsets
|
|
Concept
|
Polymerase Chain Reaction
|
|
Concept
|
Granulocyte Colony-Stimulating Factor
|
|
Concept
|
Food-Drug Interactions
|
|
Concept
|
Patient Selection
|
|
Concept
|
Receptor, ErbB-2
|
|
Concept
|
Lymphoma, Large B-Cell, Diffuse
|
|
Concept
|
Cyclin-Dependent Kinases
|
|
Concept
|
Intellectual Property
|
|
Concept
|
Menogaril
|
|
Concept
|
DNA Methylation
|
|
Concept
|
Naphthalimides
|
|
Concept
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma
|
|
Concept
|
Ritonavir
|
|
Concept
|
Dietary Supplements
|
|
Concept
|
Proto-Oncogene Proteins c-met
|
|
Concept
|
Interleukin-17
|
|
Concept
|
Gadolinium DTPA
|
|
Concept
|
O(6)-Methylguanine-DNA Methyltransferase
|
|
Concept
|
Phosphatidylinositol 3-Kinases
|
|
Concept
|
Receptor, trkA
|
|
Concept
|
Receptor, EphA5
|
|
Concept
|
Aldehyde Oxidase
|
|
Concept
|
Organic Anion Transporters
|
|
Concept
|
Medical Order Entry Systems
|
|
Concept
|
Comparative Effectiveness Research
|
|
Concept
|
Ethics Committees, Research
|
|
Concept
|
Janus Kinase 2
|
|
Concept
|
Genome-Wide Association Study
|
|
Concept
|
Pathology, Molecular
|
|
Concept
|
Precision Medicine
|
|
Concept
|
Citrus paradisi
|
|
Concept
|
Antibodies, Monoclonal, Murine-Derived
|
|
Concept
|
Pain Management
|
|
Concept
|
Ribosomal Protein S6 Kinases, 70-kDa
|
|
Concept
|
Vascular Endothelial Growth Factor A
|
|
Concept
|
Depsipeptides
|
|
Concept
|
Intracellular Signaling Peptides and Proteins
|
|
Concept
|
Cytochrome P-450 CYP3A
|
|
Concept
|
Protein Kinase C-alpha
|
|
Concept
|
Kaplan-Meier Estimate
|
|
Concept
|
Drug Discovery
|
|
Concept
|
Aldehyde Dehydrogenase
|
|
Concept
|
Anilides
|
|
Concept
|
Anthracenes
|
|
Concept
|
Immunotoxins
|
|
Concept
|
Axons
|
|
Concept
|
Benzenesulfonates
|
|
Concept
|
Blood Cell Count
|
|
Concept
|
Body Surface Area
|
|
Concept
|
Brain Neoplasms
|
|
Concept
|
Carbolines
|
|
Concept
|
Catechin
|
|
Concept
|
Catechol O-Methyltransferase
|
|
Concept
|
Chlorambucil
|
|
Concept
|
Communication
|
|
Concept
|
Cytosine
|
|
Concept
|
Deoxycytidine
|
|
Concept
|
Drug Eruptions
|
|
Concept
|
Dietary Fats
|
|
Concept
|
Doxorubicin
|
|
Concept
|
Government
|
|
Concept
|
Indenes
|
|
Concept
|
Injections, Subcutaneous
|
|
Concept
|
Insurance, Health, Reimbursement
|
|
Concept
|
Leukemia, Hairy Cell
|
|
Concept
|
Lymphocytes
|
|
Concept
|
Lymphoma, Non-Hodgkin
|
|
Concept
|
Monocytes
|
|
Concept
|
Morphine Derivatives
|
|
Concept
|
Naphthyridines
|
|
Concept
|
Neoplasm Invasiveness
|
|
Concept
|
Niacinamide
|
|
Concept
|
Nitrophenols
|
|
Concept
|
Oligonucleotides
|
|
Concept
|
Omeprazole
|
|
Concept
|
Orphan Drug Production
|
|
Concept
|
Patient Compliance
|
|
Concept
|
Peptides
|
|
Concept
|
Phenotype
|
|
Concept
|
Physician-Patient Relations
|
|
Concept
|
Polyneuropathies
|
|
Concept
|
Population
|
|
Concept
|
Predictive Value of Tests
|
|
Concept
|
Prospective Studies
|
|
Concept
|
Serine Endopeptidases
|
|
Concept
|
T-Lymphocytes
|
|
Concept
|
Thymine
|
|
Concept
|
Tramadol
|
|
Concept
|
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
|
|
Concept
|
Granulocyte-Macrophage Colony-Stimulating Factor
|
|
Concept
|
Oligonucleotides, Antisense
|
|
Concept
|
Anticarcinogenic Agents
|
|
Concept
|
Hospital Mortality
|
|
Concept
|
Pharmacoepidemiology
|
|
Concept
|
DNA Primers
|
|
Concept
|
Neuroendocrine Tumors
|
|
Concept
|
Macrolides
|
|
Concept
|
Point-of-Care Systems
|
|
Concept
|
Genetic Predisposition to Disease
|
|
Concept
|
Maximum Tolerated Dose
|
|
Concept
|
Genomics
|
|
Concept
|
Organic Cation Transporter 1
|
|
Concept
|
Genetic Privacy
|
|
Concept
|
Consent Forms
|
|
Concept
|
MicroRNAs
|
|
Concept
|
Transforming Growth Factor beta3
|
|
Concept
|
Medication Adherence
|
|
Concept
|
Evidence-Based Practice
|
|
Concept
|
Young Adult
|
|
Concept
|
Off-Label Use
|
|
Concept
|
Drug Recalls
|
|
Concept
|
Patient Safety
|
|
Academic Article
|
Rapid response of B-cell prolymphocytic leukemia to 2-chlorodeoxyadenosine.
|
|
Academic Article
|
5-Fluorouracil, hydroxyurea and escalating doses of iododeoxyuridine with concomitant radiotherapy for malignant gliomas: a clinical and pharmacologic analysis.
|
|
Academic Article
|
Phase I study of amonafide dosing based on acetylator phenotype.
|
|
Academic Article
|
Statistical and ethical issues in the design and conduct of phase I and II clinical trials of new anticancer agents.
|
|
Academic Article
|
Cisplatin, fluorouracil, and leucovorin augmented by interferon alfa-2b in head and neck cancer: a clinical and pharmacologic analysis.
|
|
Academic Article
|
Individualizing dosing of cancer chemotherapy.
|
|
Academic Article
|
Phase I study of suramin administered by intermittent infusion without adaptive control to cancer patients: update of two expanded dose levels near the maximally tolerated dose.
|
|
Academic Article
|
Dose-escalation trial of cladribine using five daily intravenous infusions in patients with advanced hematologic malignancies.
|
|
Academic Article
|
Pharmacodynamics of fluorouracil-based induction chemotherapy in advanced head and neck cancer.
|
|
Academic Article
|
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.
|
|
Academic Article
|
Pharmacodynamic modeling of prolonged administration of etoposide.
|
|
Academic Article
|
Limited-sampling models for irinotecan pharmacokinetics-pharmacodynamics: prediction of biliary index and intestinal toxicity.
|
|
Academic Article
|
Therapeutic relevance of pharmacokinetics and pharmacodynamics.
|
|
Academic Article
|
Ethical issues in phase I oncology research: a comparison of investigators and institutional review board chairpersons.
|
|
Academic Article
|
Data modifications to phase I study of suramin.
|
|
Academic Article
|
Individualized dosing of amonafide based on a pharmacodynamic model incorporating acetylator phenotype and gender.
|
|
Academic Article
|
New phase I trial methodology.
|
|
Academic Article
|
Suramin: is adaptive control necessary?
|
|
Academic Article
|
Learning from our patients: one participant's impact on clinical trial research and informed consent.
|
|
Academic Article
|
Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients.
|
|
Academic Article
|
Study of cohort-specific consent and patient control in phase I cancer trials.
|
|
Academic Article
|
A phase II study of 9-aminocamptothecin in advanced non-small-cell lung cancer.
|
|
Academic Article
|
Phase I study of concomitant chemoradiotherapy with paclitaxel, fluorouracil, and hydroxyurea with granulocyte colony-stimulating factor support for patients with poor-prognosis cancer of the head and neck.
|
|
Academic Article
|
Phase I study of 3'-deamino-3'-(2-methoxy-4-morpholinyl)doxorubicin (FCE 23762, PNU 152243) administered on a daily x3 schedule.
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of oral 9-aminocamptothecin (NSC-603071).
|
|
Academic Article
|
Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2.
|
|
Academic Article
|
Phase I study of treatment with oral 13-cis-retinoic acid, subcutaneous interferon alfa-2a, cisplatin, and 24-hour infusion 5-fluorouracil/leucovorin.
|
|
Academic Article
|
Promising new agents in oncologic treatment.
|
|
Academic Article
|
Pharmacokinetics and pharmacodynamics of oltipraz as a chemopreventive agent.
|
|
Academic Article
|
Phase II trial of paclitaxel and topotecan with granulocyte colony-stimulating factor support in stage IV breast cancer.
|
|
Academic Article
|
Oral chemotherapy: rationale and future directions.
|
|
Academic Article
|
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes.
|
|
Academic Article
|
New perspectives on the toxicity of etoposide.
|
|
Academic Article
|
Thymidylate synthase expression and response to neoadjuvant chemotherapy in patients with advanced head and neck cancer.
|
|
Academic Article
|
Phase I and pharmacokinetic trial of gemcitabine in patients with hepatic or renal dysfunction: Cancer and Leukemia Group B 9565.
|
|
Academic Article
|
Phenotype-genotype correlation of in vitro SN-38 (active metabolite of irinotecan) and bilirubin glucuronidation in human liver tissue with UGT1A1 promoter polymorphism.
|
|
Academic Article
|
O6-benzylguanine in humans: metabolic, pharmacokinetic, and pharmacodynamic findings.
|
|
Academic Article
|
Phase I and pharmacokinetic trial of paclitaxel in patients with hepatic dysfunction: Cancer and Leukemia Group B 9264.
|
|
Academic Article
|
Phase I study of ZD9331 on short daily intravenous bolus infusion for 5 days every 3 weeks with fixed dosing recommendations.
|
|
Academic Article
|
Screening for sources of interindividual pharmacokinetic variability in anticancer drug therapy: utility of population analysis.
|
|
Academic Article
|
Phase I Trial of ISIS 5132, an antisense oligonucleotide inhibitor of c-raf-1, administered by 24-hour weekly infusion to patients with advanced cancer.
|
|
Academic Article
|
Chronic daily low dose of 4-methyl-5-(2-pyrazinyl)-1,2-dithiole-3-thione (Oltipraz) in patients with previously resected colon polyps and first degree female relatives of breast cancer patients.
|
|
Academic Article
|
Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and LeukemiaGroup B study.
|
|
Academic Article
|
Flavopiridol metabolism in cancer patients is associated with the occurrence of diarrhea.
|
|
Academic Article
|
Rationale for phase I study of UFT plus leucovorin and oral JM-216.
|
|
Academic Article
|
Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit?
|
|
Academic Article
|
Pharmacology of 21-day oral etoposide given in combination with i.v. cisplatin in patients with extensive-stage small cell lung cancer: a cancer and leukemia group B study (CALGB 9062).
|
|
Academic Article
|
Pharmacogenetics and cancer chemotherapy.
|
|
Academic Article
|
Quantitative analysis of ethical issues in phase I trials: a survey interview of 144 advanced cancer patients.
|
|
Academic Article
|
A phase I study of oral uracil/ftorafur (UFT) plus leucovorin and bis-acetato-ammine-dichloro-cyclohexylamine-platinum IV (JM-216) each given over 14 days every 28 days.
|
|
Academic Article
|
Pharmacogenetics in cancer etiology and chemotherapy.
|
|
Academic Article
|
Phase I study of eniluracil, a dihydropyrimidine dehydrogenase inactivator, and oral 5-fluorouracil with radiation therapy in patients with recurrent or advanced head and neck cancer.
|
|
Academic Article
|
Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides.
|
|
Academic Article
|
5-fluorouracil pharmacokinetics: causes for variability and strategies for modulation in cancer chemotherapy.
|
|
Academic Article
|
Dear doctor: we really are not sure what dose of capecitabine you should prescribe for your patient.
|
|
Academic Article
|
Estimation of the effect of food on the disposition of oral 5-fluorouracil in combination with eniluracil.
|
|
Academic Article
|
Irinotecan dosing: does the CPT in CPT-11 stand for "Can't Predict Toxicity"?
|
|
Academic Article
|
Update on pharmacogenetics in cancer chemotherapy.
|
|
Academic Article
|
A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer.
|
|
Academic Article
|
Laboratory and clinical studies of biochemical modulation by hydroxyurea.
|
|
Academic Article
|
Endostatin: are the 2 years up yet?
|
|
Academic Article
|
Pharmacogenetics: a tool for individualizing antineoplastic therapy.
|
|
Academic Article
|
Conflict-of-interest policies.
|
|
Academic Article
|
Phase I clinical and pharmacogenetic study of weekly TAS-103 in patients with advanced cancer.
|
|
Academic Article
|
Pharmacogenetics of anticancer agents: lessons from amonafide and irinotecan.
|
|
Academic Article
|
Anticancer drug discovery and development throughout the world.
|
|
Academic Article
|
Troxacitabine in patients with refractory leukemia.
|
|
Academic Article
|
Determination of the optimal modulatory dose of O6-benzylguanine in patients with surgically resectable tumors.
|
|
Academic Article
|
Randomized study of three different doses of suramin administered with a fixed dosing schedule in patients with advanced prostate cancer: results of intergroup 0159, cancer and leukemia group B 9480.
|
|
Academic Article
|
A phase I study of liposomal doxorubicin (Doxil) with topotecan.
|
|
Academic Article
|
Pharmacogenetics in cancer treatment.
|
|
Academic Article
|
Phase I study of pegylated liposomal doxorubicin, paclitaxel, and cisplatin in patients with advanced solid tumors.
|
|
Academic Article
|
Five-day infusion of fluorodeoxyuridine with high-dose oral leucovorin: a phase I study.
|
|
Academic Article
|
Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer.
|
|
Academic Article
|
Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.
|
|
Academic Article
|
A pharmacogenetic study of uridine diphosphate-glucuronosyltransferase 2B7 in patients receiving morphine.
|
|
Academic Article
|
Correspondence re: Raida, M. et al., prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)-related toxicity compared with controls.
|
|
Academic Article
|
Phase I study to evaluate multiple regimens of intravenous 5-fluorouracil administered in combination with weekly gemcitabine in patients with advanced solid tumors: a potential broadly active regimen for advanced solid tumor malignancies.
|
|
Academic Article
|
Population pharmacokinetic model for irinotecan and two of its metabolites, SN-38 and SN-38 glucuronide.
|
|
Academic Article
|
Pharmacogenomics: road to anticancer therapeutics nirvana?
|
|
Academic Article
|
A phase I and pharmacokinetic study of irinotecan in patients with hepatic or renal dysfunction or with prior pelvic radiation: CALGB 9863.
|
|
Academic Article
|
Epirubicin glucuronidation is catalyzed by human UDP-glucuronosyltransferase 2B7.
|
|
Academic Article
|
Estimation of the glomerular filtration rate in cancer patients: a new formula for new drugs.
|
|
Academic Article
|
Relationship of baseline serum bilirubin to efficacy and toxicity of single-agent irinotecan in patients with metastatic colorectal cancer.
|
|
Academic Article
|
Clinical trial designs for cytostatic agents.
|
|
Academic Article
|
Paradoxical relationship between acetylator phenotype and amonafide toxicity.
|
|
Academic Article
|
Treatment of chemotherapy-induced anemia with recombinant human erythropoietin in cancer patients.
|
|
Academic Article
|
A phase I study of cantuzumab mertansine administered as a single intravenous infusion once weekly in patients with advanced solid tumors.
|
|
Academic Article
|
Dose-ranging study of the safety and pharmacokinetics of atrasentan in patients with refractory malignancies.
|
|
Academic Article
|
Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan.
|
|
Academic Article
|
Randomized discontinuation design: application to cytostatic antineoplastic agents.
|
|
Academic Article
|
A phase I trial of escalating doses of trastuzumab combined with daily subcutaneous interleukin 2: report of cancer and leukemia group B 9661.
|
|
Academic Article
|
A phase I trial of gemcitabine plus cladribine in patients with advanced hematologic malignant diseases.
|
|
Academic Article
|
A phase I study of the oral combination of CI-994, a putative histone deacetylase inhibitor, and capecitabine.
|
|
Academic Article
|
Weekly, high-dose paclitaxel in advanced lung carcinoma: a phase II study with pharmacokinetics by the Cancer and Leukemia Group B.
|
|
Academic Article
|
Irinotecan treatment in cancer patients with UGT1A1 polymorphisms.
|
|
Academic Article
|
Successful implementation of the randomized discontinuation trial design: an application to the study of the putative antiangiogenic agent carboxyaminoimidazole in renal cell carcinoma--CALGB 69901.
|
|
Academic Article
|
Modulation of irinotecan with cyclosporine: a phase II trial in advanced colorectal cancer.
|
|
Academic Article
|
Pharmacokinetic variability of anticancer agents.
|
|
Academic Article
|
Delivery of a liposomal c-raf-1 antisense oligonucleotide by weekly bolus dosing in patients with advanced solid tumors: a phase I study.
|
|
Academic Article
|
Pharmacokinetics, pharmacodynamics and adherence to oral topotecan in myelodysplastic syndromes: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Phase II oncology trials: let's be positive.
|
|
Academic Article
|
Effects of ketoconazole on glucuronidation by UDP-glucuronosyltransferase enzymes.
|
|
Academic Article
|
Randomized phase II trials and prostate-specific antigen endpoints in prostate cancer: much ado about nothing?
|
|
Academic Article
|
Prescribing oral chemotherapy.
|
|
Academic Article
|
Hepatocyte nuclear factor-1 alpha is associated with UGT1A1, UGT1A9 and UGT2B7 mRNA expression in human liver.
|
|
Academic Article
|
A comparison of the pharmacokinetics and pharmacodynamics of docetaxel between African-American and Caucasian cancer patients: CALGB 9871.
|
|
Academic Article
|
Global gene expression as a function of germline genetic variation.
|
|
Academic Article
|
From bedside to bench to bedside to clinical practice: an odyssey with irinotecan.
|
|
Academic Article
|
Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis.
|
|
Academic Article
|
Response to high dose cyclophosphamide with GM-CSF in Merkel cell tumor.
|
|
Academic Article
|
Heritability and linkage analysis of sensitivity to cisplatin-induced cytotoxicity.
|
|
Academic Article
|
Clarification regarding "phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties" and the accompanying commentary, "phase II cancer trials: out of control?".
|
|
Academic Article
|
Relationship of EGFR mutations, expression, amplification, and polymorphisms to epidermal growth factor receptor inhibitors in the NCI60 cell lines.
|
|
Academic Article
|
Finding the right dose.
|
|
Academic Article
|
Pharmacogenomics: challenges and opportunities.
|
|
Academic Article
|
Prospective evaluation of the relationship of patient age and paclitaxel clinical pharmacology: Cancer and Leukemia Group B (CALGB 9762).
|
|
Academic Article
|
Irinogenetics: what is the right star?
|
|
Academic Article
|
Phase II placebo-controlled randomized discontinuation trial of sorafenib in patients with metastatic renal cell carcinoma.
|
|
Academic Article
|
Interpreting disparate responses to cancer therapy: the role of human population genetics.
|
|
Academic Article
|
Phase II trials published in 2002: a cross-specialty comparison showing significant design differences between oncology trials and other medical specialties.
|
|
Academic Article
|
Searching for tissue-specific expression pattern-linked nucleotides of UGT1A isoforms.
|
|
Academic Article
|
Inside information: Financial conflicts of interest for research subjects in early phase clinical trials.
|
|
Academic Article
|
Interpreting P values in pharmacogenetic studies: a call for process and perspective.
|
|
Academic Article
|
CYP2B6, CYP3A4, and CYP2C19 are responsible for the in vitro N-demethylation of meperidine in human liver microsomes.
|
|
Academic Article
|
Pharmacogenomic and pharmacokinetic determinants of erlotinib toxicity.
|
|
Academic Article
|
The value meal: how to save $1,700 per month or more on lapatinib.
|
|
Academic Article
|
Clinical pharmacokinetics of high-dose leucovorin calcium after intravenous and oral administration.
|
|
Academic Article
|
A Phase II trial of suramin monthly x 3 for hormone-refractory prostate carcinoma.
|
|
Academic Article
|
Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
|
|
Academic Article
|
Phase II studies of modern drugs directed against new targets: if you are fazed, too, then resist RECIST.
|
|
Academic Article
|
Phase I trial of orally administered CEP-701, a novel neurotrophin receptor-linked tyrosine kinase inhibitor.
|
|
Academic Article
|
Prediction of CYP3A4 enzyme activity using haplotype tag SNPs in African Americans.
|
|
Academic Article
|
Genomic assessment of a multikinase inhibitor, sorafenib, in a rodent model of pulmonary hypertension.
|
|
Academic Article
|
Genome-wide identification of genetic determinants for the cytotoxicity of perifosine.
|
|
Academic Article
|
A phase I study of antisense oligonucleotide GTI-2040 given by continuous intravenous infusion in patients with advanced solid tumors.
|
|
Academic Article
|
Single nucleotide polymorphism discovery and functional assessment of variation in the UDP-glucuronosyltransferase 2B7 gene.
|
|
Academic Article
|
The Werner's syndrome 4330T>C (Cys1367Arg) gene variant does not affect the in vitro cytotoxicity of topoisomerase inhibitors and platinum compounds.
|
|
Academic Article
|
Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma.
|
|
Academic Article
|
Conservative management of primary cervical lymphoma using combination chemotherapy: a case report.
|
|
Academic Article
|
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
|
|
Academic Article
|
R(+)XK469 inhibits hydroxylation of S-warfarin by CYP2C9.
|
|
Academic Article
|
Sequential treatment of hairy cell leukemia: a new role for interferon.
|
|
Academic Article
|
Etoposide pathway.
|
|
Academic Article
|
Pharmacologically based dosing of etoposide: a means of safely increasing dose intensity.
|
|
Academic Article
|
Hairy cell leukemia. Current management.
|
|
Academic Article
|
The cancer and leukemia group B pharmacology and experimental therapeutics committee: a historical perspective.
|
|
Academic Article
|
Ambulatory monitoring detects sorafenib-induced blood pressure elevations on the first day of treatment.
|
|
Academic Article
|
A pharmacogenetic study of vorinostat glucuronidation.
|
|
Academic Article
|
Testing the wrong hypothesis in phase II oncology trials: there is a better alternative.
|
|
Academic Article
|
Other paradigms: better treatments are identified by better trials: the value of randomized phase II studies.
|
|
Academic Article
|
Evaluating the activity of temsirolimus in neuroendocrine cancer.
|
|
Academic Article
|
Complementary and alternative medicine among advanced cancer patients enrolled on phase I trials: a study of prognosis, quality of life, and preferences for decision making.
|
|
Academic Article
|
Pharmacokinetic modulation of oral etoposide by ketoconazole in patients with advanced cancer.
|
|
Academic Article
|
In vitro and in vivo oxidative metabolism and glucuronidation of anastrozole.
|
|
Academic Article
|
Dose reduction of etoposide in jaundiced patients.
|
|
Academic Article
|
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
|
|
Academic Article
|
Attitudes toward research participation and investigator conflicts of interest among advanced cancer patients participating in early phase clinical trials.
|
|
Academic Article
|
A phase I study of continuous infusion cilengitide in patients with solid tumors.
|
|
Academic Article
|
A phase I study of sirolimus and bevacizumab in patients with advanced malignancies.
|
|
Academic Article
|
Biomarkers in phase I oncology trials: signal, noise, or expensive distraction?
|
|
Academic Article
|
The effect of thalidomide on the pharmacokinetics of irinotecan and metabolites in advanced solid tumor patients.
|
|
Academic Article
|
A functional common polymorphism in a Sp1 recognition site of the epidermal growth factor receptor gene promoter.
|
|
Academic Article
|
Recommended changes to oncology clinical trial design: revolution or evolution?
|
|
Academic Article
|
The investigational drug steering committee.
|
|
Academic Article
|
Ethical, scientific, and regulatory perspectives regarding the use of placebos in cancer clinical trials.
|
|
Academic Article
|
What is the choice of treatment for hairy cell leukemia?
|
|
Academic Article
|
Flushing oral oncology drugs down the toilet.
|
|
Academic Article
|
Models of excellence: improving oncology drug development.
|
|
Academic Article
|
Why RECIST works and why it should stay--reply to counterpoint.
|
|
Academic Article
|
Alpha-2 interferon therapy of hairy-cell leukemia: a multicenter study of 64 patients.
|
|
Academic Article
|
Current dilemmas in carboplatin dosing.
|
|
Academic Article
|
Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer.
|
|
Academic Article
|
Nonprofit biomedical companies.
|
|
Academic Article
|
Limited sampling models for doxorubicin pharmacokinetics.
|
|
Academic Article
|
Optimising the design of phase II oncology trials: the importance of randomisation.
|
|
Academic Article
|
Interferon treatment for hairy cell leukemia. An update on a cohort of 69 patients treated from 1983 to 1986.
|
|
Academic Article
|
Prognostic factors for survival in patients treated in phase I clinical trials.
|
|
Academic Article
|
Uridine 5'-diphospho-glucuronosyltransferase genetic polymorphisms and response to cancer chemotherapy.
|
|
Academic Article
|
Bar the windows but open the door to randomization.
|
|
Academic Article
|
Resampling phase III data to assess phase II trial designs and endpoints.
|
|
Academic Article
|
Treatment of hairy cell leukemia with recombinant alpha 2 interferon.
|
|
Academic Article
|
A randomized study of inpatient versus outpatient continuous infusion chemotherapy for patients with locally advanced head and neck cancer.
|
|
Academic Article
|
Relapse after interferon alfa-2b therapy for hairy-cell leukemia: analysis of prognostic variables.
|
|
Academic Article
|
The UGT1A1*28 polymorphism correlates with erlotinib's effect on SN-38 glucuronidation.
|
|
Academic Article
|
A programmable and implantable pumping system for systemic chemotherapy: a performance analysis in 52 patients.
|
|
Academic Article
|
A genome-wide association study of overall survival in pancreatic cancer patients treated with gemcitabine in CALGB 80303.
|
|
Academic Article
|
Sequential evaluation of alpha-2b-interferon treatment in 128 patients with hairy cell leukemia.
|
|
Academic Article
|
Durability of responses to interferon alfa-2b in advanced hairy cell leukemia.
|
|
Academic Article
|
The 1200 patients project: creating a new medical model system for clinical implementation of pharmacogenomics.
|
|
Academic Article
|
Inconsistent labeling of food effect for oral agents across therapeutic areas: differences between oncology and non-oncology products.
|
|
Academic Article
|
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.
|
|
Academic Article
|
Pharmacogenomics: will the promise be fulfilled?
|
|
Academic Article
|
The role of interferon in the treatment of hairy cell leukemia.
|
|
Academic Article
|
TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?
|
|
Academic Article
|
Value-based insurance design: aligning incentives, benefits, and evidence in oncology.
|
|
Academic Article
|
Germline pharmacogenomics in oncology: decoding the patient for targeting therapy.
|
|
Academic Article
|
Pushing the envelope: informed consent in phase I trials.
|
|
Academic Article
|
Importance of food effects for oral oncology drugs.
|
|
Academic Article
|
Pharmacogenomics and patient care: one size does not fit all.
|
|
Academic Article
|
Population pharmacodynamic study of amonafide: a Cancer and Leukemia Group B study.
|
|
Academic Article
|
Sequential therapy with dacarbazine and carmustine: a phase I study.
|
|
Academic Article
|
Phase I trial of a genetically engineered interleukin-2 fusion toxin (DAB486IL-2) as a 6 hour intravenous infusion in patients with hematologic malignancies.
|
|
Academic Article
|
Human pharmacokinetics, excretion, and metabolism of the anthracycline antibiotic menogaril (7-OMEN, NSC 269148) and their correlation with clinical toxicities.
|
|
Academic Article
|
Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer.
|
|
Academic Article
|
Report of a multi-institutional study of 193 patients with hairy cell leukemia treated with interferon-alfa2b.
|
|
Academic Article
|
Therapy-related acute myeloid leukemia secondary to inhibitors of topoisomerase II: from the bedside to the target genes.
|
|
Academic Article
|
Limited sampling model for vinblastine pharmacokinetics.
|
|
Academic Article
|
Bootstrap validation of pharmacodynamic models defined via stepwise linear regression.
|
|
Academic Article
|
The HapMap Resource is Providing New Insights into Ourselves and its Application to Pharmacogenomics.
|
|
Academic Article
|
A phase I and pharmacokinetic study of the quinoxaline antitumour Agent R(+)XK469 in patients with advanced solid tumours.
|
|
Academic Article
|
Phase I study of paclitaxel and topotecan in patients with advanced tumors: a cancer and leukemia group B study.
|
|
Academic Article
|
Five-day infusional fluorodeoxyuridine with oral leucovorin and escalating doses of interferon alpha-2b: a phase I study.
|
|
Academic Article
|
Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics.
|
|
Academic Article
|
Dose-escalation models for combination phase I trials in oncology.
|
|
Academic Article
|
Analysis of the yield of phase II combination therapy trials in medical oncology.
|
|
Academic Article
|
RECIST: no longer the sharpest tool in the oncology clinical trials toolbox---point.
|
|
Academic Article
|
Human plasma pharmacokinetics of thiotepa following administration of high-dose thiotepa and cyclophosphamide.
|
|
Academic Article
|
Limited sampling models for amonafide (NSC 308847) pharmacokinetics.
|
|
Academic Article
|
Interpatient and intrapatient variability in vinblastine pharmacokinetics.
|
|
Academic Article
|
Interferon treatment for hairy cell leukemia: an update on a cohort of 69 patients treated from 1983-1986.
|
|
Academic Article
|
Perceptions of cancer patients and their physicians involved in phase I trials.
|
|
Academic Article
|
Phase I clinical and pharmacologic study of eniluracil plus fluorouracil in patients with advanced cancer.
|
|
Academic Article
|
Amonafide: An active agent in the treatment of previously untreated advanced breast cancer--a cancer and leukemia group B study (CALGB 8642).
|
|
Academic Article
|
Drug combinations: dangerous liaisons or great expectations?
|
|
Academic Article
|
Phase I clinical and pharmacological study of O6-benzylguanine followed by carmustine in patients with advanced cancer.
|
|
Academic Article
|
Body surface area as a determinant of pharmacokinetics and drug dosing.
|
|
Academic Article
|
Phase 1 dose escalation study of docetaxel with filgrastim support in patients with advanced solid tumors.
|
|
Academic Article
|
Phase I study of an oral formulation of ZD9331 administered daily for 28 days.
|
|
Academic Article
|
Phase I and pharmacokinetic study of 24-hour infusion 5-fluorouracil and leucovorin in patients with organ dysfunction.
|
|
Academic Article
|
Quality of life impact of three different doses of suramin in patients with metastatic hormone-refractory prostate carcinoma: results of Intergroup O159/Cancer and Leukemia Group B 9480.
|
|
Academic Article
|
Dose-ranging pharmacodynamic study of tipifarnib (R115777) in patients with relapsed and refractory hematologic malignancies.
|
|
Academic Article
|
Modulation of vinblastine resistance with cyclosporine: a phase I study.
|
|
Academic Article
|
Phase I study of adozelesin administered by 24-hour continuous intravenous infusion.
|
|
Academic Article
|
Measuring response in a post-RECIST world: from black and white to shades of grey.
|
|
Academic Article
|
The role of pharmacogenetics in cancer therapeutics.
|
|
Academic Article
|
Pharmacodynamics in cancer therapy.
|
|
Academic Article
|
UGT1A1*28 genotype affects the in-vitro glucuronidation of thyroxine in human livers.
|
|
Academic Article
|
Rapamycin: something old, something new, sometimes borrowed and now renewed.
|
|
Academic Article
|
A phase I and pharmacokinetic study of XK469R (NSC 698215), a quinoxaline phenoxypropionic acid derivative, in patients with refractory acute leukemia.
|
|
Academic Article
|
Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?
|
|
Academic Article
|
Phase II study of 9-aminocamptothecin in previously treated lymphomas: results of Cancer and Leukemia Group B 9551.
|
|
Academic Article
|
Efficacy and safety of sorafenib in a subset of patients with advanced soft tissue sarcoma from a Phase II randomized discontinuation trial.
|
|
Academic Article
|
Plasma pharmacokinetics of high-dose oral melphalan in patients treated with trialkylator chemotherapy and autologous bone marrow reinfusion.
|
|
Academic Article
|
Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
|
|
Academic Article
|
Value-based insurance design in oncology.
|
|
Academic Article
|
Phase-I trial of Thiotepa, granulocyte-macrophage colony-stimulating factor and prednisone or pentoxifylline in patients with refractory solid tumors.
|
|
Academic Article
|
Opportunities and challenges in the development of experimental drug combinations for cancer.
|
|
Academic Article
|
Oncology micro-cap stocks: caveat emptor!
|
|
Academic Article
|
Rapid response to 2'-deoxycoformycin in advanced hairy cell leukemia after failure of interferons alpha and gamma.
|
|
Academic Article
|
Prognostic variables in hairy cell leukemia after splenectomy as initial therapy.
|
|
Academic Article
|
Skeletal complications in hairy cell leukemia: diagnosis and therapy.
|
|
Academic Article
|
Integration of cell line and clinical trial genome-wide analyses supports a polygenic architecture of Paclitaxel-induced sensory peripheral neuropathy.
|
|
Academic Article
|
Unsupported off-label chemotherapy in metastatic colon cancer.
|
|
Academic Article
|
Evaluation of food effect on pharmacokinetics of vismodegib in advanced solid tumor patients.
|
|
Academic Article
|
Glucuronidation by UGT1A1 is the dominant pathway of the metabolic disposition of belinostat in liver cancer patients.
|
|
Academic Article
|
A novel fully automated molecular diagnostic system (AMDS) for colorectal cancer mutation detection.
|
|
Academic Article
|
Time to tumor growth: a model end point and new metric system for oncology clinical trials.
|
|
Academic Article
|
The relationship of polymorphisms in ABCC2 and SLCO1B3 with docetaxel pharmacokinetics and neutropenia: CALGB 60805 (Alliance).
|
|
Academic Article
|
Genome-wide interrogation of longitudinal FEV1 in children with asthma.
|
|
Academic Article
|
Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis.
|
|
Academic Article
|
Estimation of Progression-Free Survival for All Treated Patients in the Randomized Discontinuation Trial Design.
|
|
Academic Article
|
Dose-finding and pharmacokinetic study to optimize the dosing of irinotecan according to the UGT1A1 genotype of patients with cancer.
|
|
Academic Article
|
Phase I dose-escalation study of onartuzumab as a single agent and in combination with bevacizumab in patients with advanced solid malignancies.
|
|
Academic Article
|
Targeted therapies: redefining the primary objective of phase I oncology trials.
|
|
Academic Article
|
Meaningful use of pharmacogenetics.
|
|
Academic Article
|
Tumour heterogeneity in the clinic.
|
|
Academic Article
|
Evaluation of utility of pharmacokinetic studies in phase I trials of two oncology drugs.
|
|
Academic Article
|
Incorporating biomarkers into drug labeling.
|
|
Academic Article
|
Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 gene.
|
|
Academic Article
|
Challenges in interpreting the evidence for genetic predictors of ototoxicity.
|
|
Academic Article
|
Loss of heterozygosity at the CYP2D6 locus in breast cancer: implications for germline pharmacogenetic studies.
|
|
Academic Article
|
Germline variants and advanced colorectal adenomas: adenoma prevention with celecoxib trial genome-wide association study.
|
|
Academic Article
|
Functional characterization of ABCC2 promoter polymorphisms and allele-specific expression.
|
|
Academic Article
|
Unmet needs in preventing adverse drug-drug interactions.
|
|
Academic Article
|
Polygenic inheritance of paclitaxel-induced sensory peripheral neuropathy driven by axon outgrowth gene sets in CALGB 40101 (Alliance).
|
|
Academic Article
|
First-in-human phase I study of Lurbinectedin (PM01183) in patients with advanced solid tumors.
|
|
Academic Article
|
Vemurafenib oral bioavailability: an insoluble problem.
|
|
Academic Article
|
Adoption of a clinical pharmacogenomics implementation program during outpatient care--initial results of the University of Chicago "1,200 Patients Project".
|
|
Academic Article
|
The development of a financial toxicity patient-reported outcome in cancer: The COST measure.
|
|
Academic Article
|
Forecasting unanticipated consequences of "The Sunshine Act": mostly cloudy.
|
|
Academic Article
|
Circadian variation in plasma 5-fluorouracil concentrations during a 24 hour constant-rate infusion.
|
|
Academic Article
|
Genetic factors affecting gene transcription and catalytic activity of UDP-glucuronosyltransferases in human liver.
|
|
Academic Article
|
User beware: we need more science and less art when measuring financial toxicity in oncology.
|
|
Academic Article
|
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469.
|
|
Academic Article
|
Re: Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA.
|
|
Academic Article
|
The impact of industry on oncology research and practice.
|
|
Academic Article
|
Glucuronidation of OTS167 in Humans Is Catalyzed by UDP-Glucuronosyltransferases UGT1A1, UGT1A3, UGT1A8, and UGT1A10.
|
|
Academic Article
|
Evidence for Clinical Implementation of Pharmacogenomics in Cardiac Drugs.
|
|
Academic Article
|
Redefining the primary objective of phase I oncology trials.
|
|
Academic Article
|
Participation in Cancer Pharmacogenomic Studies: A Study of 8456 Patients Registered to Clinical Trials in the Cancer and Leukemia Group B (Alliance).
|
|
Academic Article
|
Impact of the 2010 Consensus Recommendations of the Clinical Trial Design Task Force of the NCI Investigational Drug Steering Committee.
|
|
Academic Article
|
Harmonization of Renal Function Assessment Is Needed During Early Clinical Development of Oncology Drugs.
|
|
Academic Article
|
Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials.
|
|
Academic Article
|
The Outlier in All of Us: Why Implementing Pharmacogenomics Could Matter for Everyone.
|
|
Academic Article
|
Taking a Measured Approach to Toxicity Data in Phase I Oncology Clinical Trials.
|
|
Academic Article
|
Casting doubt on the scientific utility of post-treatment biopsies in phase 1 trials.
|
|
Academic Article
|
Reply to T.A. Yap et al.
|
|
Academic Article
|
Measuring financial toxicity as a clinically relevant patient-reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST).
|
|
Academic Article
|
Drug-Drug Interactions With Oral Antineoplastic Agents.
|
|
Academic Article
|
Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy.
|
|
Academic Article
|
Genome-wide association studies of drug response and toxicity: an opportunity for genome medicine.
|
|
Academic Article
|
Obviating the Need for Serial Biopsies Through Random Assignment.
|
|
Academic Article
|
Food Effect Studies for Oncology Drug Products.
|
|
Academic Article
|
Phase I study of lurbinectedin, a synthetic tetrahydroisoquinoline that inhibits activated transcription, induces DNA single- and double-strand breaks, on a weekly × 2 every-3-week schedule.
|
|
Academic Article
|
The Pharmacogenomics Research Network Translational Pharmacogenetics Program: Outcomes and Metrics of Pharmacogenetic Implementations Across Diverse Healthcare Systems.
|
|
Academic Article
|
Providing Balance in ASCO Clinical Practice Guidelines: CYP2D6 Genotyping and Tamoxifen Efficacy.
|
|
Academic Article
|
A phase I study of XL184, a RET, VEGFR2, and MET kinase inhibitor, in patients (pts) with advanced malignancies, including pts with medullary thyroid cancer (MTC).
|
|
Academic Article
|
Phase I study of PM02734: Association of dose-limiting hepatotoxicity with plasma concentrations.
|
|
Academic Article
|
A study of informed consent (IC), age, and cognitive performance (CP) among advanced cancer patients (acp) in phase I trials.
|
|
Academic Article
|
Addition of grapefruit juice (GJ) to increase the bioavailability of high-dose weekly rapamcyin (R).
|
|
Academic Article
|
Phase I study of the safety, pharmacokinetics (PK) and pharmacodynamics (PD) of the histone deacetylase inhibitor (HDACi) PCI-24781.
|
|
Academic Article
|
Analysis of phase II studies for the year 2002: Design, conclusions and impact factors of oncology vs. non-oncology trials.
|
|
Academic Article
|
A phase I trial of GRN163L (GRN), a first-in-class telomerase inhibitor, in advanced solid tumors.
|
|
Academic Article
|
Cellular transporter pharmacogenetics in metastatic colorectal cancer: Initial analysis of C80203.
|
|
Academic Article
|
Final findings from a phase II, placebo-controlled, randomized discontinuation trial (RDT) of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC).
|
|
Academic Article
|
Phase I study of belinostat (PXD101) plus azacitidine (AZC) in patients with advanced myeloid neoplasms.
|
|
Academic Article
|
A drug interaction study of sorafenib (S) and rapamycin (R) in patients with advanced malignancies.
|
|
Academic Article
|
Development of a pharmacokinetically-guided gemcitabine (dFdC) dosing schedule to reduce potentially excessive plasma dFdC concentrations.
|
|
Academic Article
|
Pharmacogenomics-Based Point-of-Care Clinical Decision Support Significantly Alters Drug Prescribing.
|
|
Academic Article
|
Analyzing the clinical actionability of germline pharmacogenomic findings in oncology.
|
|
Academic Article
|
Metabolism of megestrol acetate in vitro and the role of oxidative metabolites.
|
|
Academic Article
|
Prospective International Randomized Phase II Study of Low-Dose Abiraterone With Food Versus Standard Dose Abiraterone In Castration-Resistant Prostate Cancer.
|
|
Academic Article
|
Do Patients With Advanced Cancer Have the Ability to Make Informed Decisions for Participation in Phase I Clinical Trials?
|
|
Academic Article
|
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validation.
|
|
Academic Article
|
Fc-gamma receptor polymorphisms, cetuximab therapy, and overall survival in the CCTG CO.20 trial of metastatic colorectal cancer.
|
|
Academic Article
|
Reply to I.F. Tannock, P. Isaacsson Velho et al, M. Tiako Meyo et al, and F.J.S.H. Woei-A-Jin et al.
|
|
Academic Article
|
Safety and Clinical Activity of Pembrolizumab and Multisite Stereotactic Body Radiotherapy in Patients With Advanced Solid Tumors.
|
|
Academic Article
|
Low-Dose Abiraterone With Food: Rebutting an Editorial.
|
|
Academic Article
|
Time Is Money: Optimizing the Scheduling of Nivolumab.
|
|
Academic Article
|
Clinical pharmacodynamic/exposure characterisation of the multikinase inhibitor ilorasertib (ABT-348) in a phase 1 dose-escalation trial.
|
|
Academic Article
|
Genomic Heterogeneity Within Individual Prostate Cancer Foci Impacts Predictive Biomarkers of Targeted Therapy.
|
|
Academic Article
|
Interventional Pharmacoeconomics-A New Discipline for a Cost-Constrained Environment.
|
|
Academic Article
|
Ethical Framework for Including Research Biopsies in Oncology Clinical Trials: American Society of Clinical Oncology Research Statement.
|
|
Academic Article
|
A Cost-Focused Alternative Cancer Medication Dispensing Strategy-"Pack Splitting".
|
|
Academic Article
|
Personalized Management of Chemotherapy-Induced Peripheral Neuropathy Based on a Patient Reported Outcome: CALGB 40502 (Alliance).
|
|
Academic Article
|
Optimal Sampling Strategies for Irinotecan (CPT-11) and its Active Metabolite (SN-38) in Cancer Patients.
|
|
Academic Article
|
Clinical evaluation of germline polymorphisms associated with capecitabine toxicity in breast cancer: TBCRC-015.
|
|
Academic Article
|
Opportunities for using in silico-based extended dosing regimens for monoclonal antibody immune checkpoint inhibitors.
|
|
Academic Article
|
Weight-Based Dosing of Pembrolizumab Every 6 Weeks in the Time of COVID-19.
|
|
Academic Article
|
Genomewide Meta-Analysis Validates a Role for S1PR1 in Microtubule Targeting Agent-Induced Sensory Peripheral Neuropathy.
|
|
Academic Article
|
Genomic Analysis of Germline Variation Associated with Survival of Patients with Colorectal Cancer Treated with Chemotherapy Plus Biologics in CALGB/SWOG 80405 (Alliance).
|
|
Academic Article
|
Oncology's "Hockey Stick" Moment for the Cost of Cancer Drugs-The Climate Is About to Change.
|
|
Academic Article
|
Ibrutinib's Cardiotoxicity-An Opportunity for Postmarketing Regulation.
|
|
Academic Article
|
COVIDOSE: A Phase II Clinical Trial of Low-Dose Tocilizumab in the Treatment of Noncritical COVID-19 Pneumonia.
|
|
Academic Article
|
Accelerated Approval of Anticancer Drugs: Lessons Learned From the Example of Olaratumab.
|
|
Academic Article
|
Implementation of pharmacogenomic testing in oncology care (PhOCus): study protocol of a pragmatic, randomized clinical trial.
|
|
Academic Article
|
Near-Equivalence: Generating Evidence to Support Alternative Cost-Effective Treatments.
|
|
Academic Article
|
The Abiraterone Dosing Chess Match With Johnson & Johnson-Back in Check.
|
|
Academic Article
|
The Right Dose: From Phase I to Clinical Practice.
|
|
Academic Article
|
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.
|
|
Academic Article
|
Appraisal and development of evidence-based clinical decision support to enable perioperative pharmacogenomic application.
|
|
Academic Article
|
Impact of CYP2D6 Pharmacogenomic Status on Pain Control Among Opioid-Treated Oncology Patients.
|
|
Academic Article
|
Creation of a pharmacogenomics patient portal complementary to an existing institutional provider-facing clinical decision support system.
|
|
Academic Article
|
Dose Optimization of Sotorasib: Is the US Food and Drug Administration Sending a Message?
|
|
Academic Article
|
Pharmacokinetic Simulation Analysis of Less Frequent Nivolumab and Pembrolizumab Dosing: Pharmacoeconomic Rationale for Dose Deescalation.
|
|
Academic Article
|
Dose Optimization of Pembrolizumab: Less May Be More.
|
|
Academic Article
|
Designing Dose-Finding Phase I Clinical Trials: Top Questions That Should Be Discussed With Your Clinical Pharmacologist.
|
|
Academic Article
|
Precision and Accuracy in the Brave New World of Basket Trials.
|
|
Academic Article
|
Pilot Findings of Pharmacogenomics in Perioperative Care: Initial Results From the First Phase of the ImPreSS Trial.
|
|
Academic Article
|
Alternative trastuzumab dosing strategies in HER2-positive early breast cancer are associated with patient out-of-pocket savings.
|
|
Academic Article
|
Lorlatinib Exposed: A Far From Optimal Dose.
|
|
Academic Article
|
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study.
|
|
Academic Article
|
Pfizer and Palbociclib in China: Analyzing an Oncology Pay-for-Performance Plan.
|
|
Academic Article
|
Drug Interactions With a Short Course of Nirmatrelvir and Ritonavir: Prescribers and Patients Beware.
|
|
Academic Article
|
Oncology Drug Prescribing: The Influences of Greed and Fear.
|
|
Academic Article
|
An Expanded Role for IRBs in the Oversight of Research Biopsies.
|
|
Academic Article
|
In Silico Re-Optimization of Atezolizumab Dosing Using Population Pharmacokinetic Simulation and Exposure-Response Simulation.
|
|
Academic Article
|
Oncology phase I trial design and conduct: time for a change - MDICT Guidelines 2022.
|
|
Academic Article
|
US Government Payer-Funded Trials to Address Oncology's Drug-Dosing Conundrum: A Congressional Call to Action?
|
|
Concept
|
Celecoxib
|
|
Concept
|
Bevacizumab
|
|
Concept
|
Imatinib Mesylate
|
|
Concept
|
Trastuzumab
|
|
Concept
|
Cetuximab
|
|
Concept
|
Rituximab
|
|
Concept
|
Capecitabine
|
|
Concept
|
Atazanavir Sulfate
|
|
Concept
|
Filgrastim
|
|
Concept
|
Erlotinib Hydrochloride
|
|
Concept
|
Abiraterone Acetate
|
|
Concept
|
Patient Reported Outcome Measures
|
|
Concept
|
Proprotein Convertase 9
|
|
Concept
|
Werner Syndrome Helicase
|
|
Concept
|
Regulatory Factor X Transcription Factors
|
|
Concept
|
Greenhouse Gases
|
|
Concept
|
Peroxisome-Targeting Signal 1 Receptor
|
|
Concept
|
Solute Carrier Organic Anion Transporter Family Member 1B3
|
|
Concept
|
X-ray Repair Cross Complementing Protein 1
|
|
Concept
|
Organophosphonates
|
|
Concept
|
Tertiary Care Centers
|
|
Concept
|
Patient Outcome Assessment
|
|
Concept
|
Prostatic Neoplasms, Castration-Resistant
|
|
Concept
|
Patient Harm
|
|
Concept
|
Cytochrome P-450 CYP2C19
|
|
Concept
|
Cytochrome P-450 CYP2B6
|
|
Concept
|
Cytochrome P-450 CYP2C8
|
|
Concept
|
Cytochrome P-450 CYP2C9
|
|
Concept
|
ErbB Receptors
|
|
Academic Article
|
Patient-centered, self-funding dose optimization trials as a route to reduce toxicity, lower cost, and improve access to cancer therapy.
|
|
Academic Article
|
Alternative Trastuzumab Dosing Schedules Are Associated With Reductions in Health Care Greenhouse Gas Emissions.
|
|
Academic Article
|
Project Optimus: Is the US Food and Drug Administration Waiving Dose Optimization for Orphan Drugs?
|
|
Academic Article
|
An Ethical and Financial Obligation for Sickle Cell Disease Gene Therapy in the United States.
|
|
Academic Article
|
Optimizing the doses of cancer drugs after usual dose finding.
|
|
Academic Article
|
Sotorasib dosing and incremental cost ineffectiveness - implications and lessons for stakeholders.
|
|
Academic Article
|
Therapeutic Drug Monitoring of Oral Oncology Drugs: Another Example of Maslow's Hammer.
|